Mironid appoints Dr Catherine Kelleher as Chief Medical Officer
October 24 2023, Glasgow, Scotland – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a serious hereditary kidney disease, today announces the appointment of Dr Catherine (Cass) Kelleher as Chief Medical Officer.
Dr Kelleher is a physician with more than 14 years experience in the biopharmaceutical industry and a further 14 years in academic medicine as an internist, nephrologist and geriatrician. She started her industry career at Amgen and has worked in multiple senior positions in drug development including nephrology and rheumatology. Cass most recently served as Chief Medical Officer at Anteris Bio and previously as Senior Vice President of Clinical Development at ChemoCentryx. Prior to joining industry, Cass was Associate Professor of Medicine at the University of Colorado.
“Mironid has the potential to improve the ADPKD disease space by offering a first-in-class, innovative molecule to treat patients with ADPKD and possibly other rare diseases,” commented Dr Cass Kelleher, Chief Medical Officer of Mironid. “I look forward to helping make this a reality, working closely with the executive team at Mironid as we work to progress our treatment into the clinic.”
“I am delighted to welcome Cass as Chief Medical Officer to the team here at Mironid,” commented Dr Neil Wilkie, Chief Executive Officer of Mironid. “Her extensive experience in drug development in rare diseases, as well as her broad medical and scientific knowledge, make her perfectly suited for this position. We continue to build a strong team with the shared goal of delivering a safe, well-tolerated and effective treatment option for all ADPKD patients.”
-ENDS-
Enquiries:
Mironid
Neil Wilkie, Chief Executive Officer
enquiries@mironid.com
ICR Consilium
Mary-Jane Elliott / Sukaina Virji / Lindsey Neville
Mironid@consilium-comms.com
About Mironid
Mironid is a biopharmaceutical company developing small molecule therapeutics for the treatment of life-threatening hereditary kidney disease. Its lead programme is for Autosomal Dominant Polycystic Kidney Disease (ADPKD), which is characterized by uncontrolled growth of fluid-filled cysts and is the most common hereditary kidney disorder, but has limited treatment options. Mironid’s first-in-class small molecule LoAc® drug candidates directly target the abnormally high kidney cAMP levels that drive cyst formation. The Company is led by an industry-experienced management team and supported by a strong advisory network and blue-chip investors including Roche Venture Fund, Epidarex Capital, Sofinnova Partners and BioGeneration Ventures. The University of Strathclyde, Scottish Investment Bank and the European Investment Fund (EIF) are also investors in Mironid.
